Samsung Biologics Co.,Ltd.
207940
株式のランク
#498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
株価
$1,028.49
時価総額
$47.88B
変化（1日）
-3.67%
変化（1年）
-18.37%
国
KR
取引 Samsung Biologics Co.,Ltd. (207940)
カテゴリー
Healthcare
Samsung Biologics Co.,Ltd.（207940）のP/B比率
October 2026 時点のP/B比率 TTM: 7.59
Samsung Biologics Co.,Ltd. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 7.59 です。2024 年末時点でのP/B比率は 6.19 でした。
Samsung Biologics Co.,Ltd. の P/B 比率の履歴（2014 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 7.59 | -27.89% |
| 2025 | 10.52 | 69.82% |
| 2024 | 6.19 | 8.43% |
| 2023 | 5.71 | -11.02% |
| 2022 | 6.42 | -46.93% |
| 2021 | 12.10 | 0.73% |
| 2020 | 12.01 | 80.63% |
| 2019 | 6.65 | 10.48% |
| 2018 | 6.02 | -8.12% |
| 2017 | 6.55 | 197.83% |
| 2016 | 2.20 | -43.49% |
| 2015 | 3.89 | -78.44% |
| 2014 | 18.05 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.6964 | -11.72% |
US
|
|
| 13.6307 | 79.69% |
US
|
|
| 4.4521 | -41.31% |
AU
|
|
| 4.2241 | -44.31% |
BE
|
|
| 6.3632 | -16.11% |
NL
|
